BNP Paribas Financial Markets Has $2.33 Million Stake in argenx SE (NASDAQ:ARGX)

BNP Paribas Financial Markets cut its stake in argenx SE (NASDAQ:ARGX - Free Report) by 48.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,292 shares of the company's stock after selling 4,050 shares during the quarter. BNP Paribas Financial Markets' holdings in argenx were worth $2,327,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Blue Trust Inc. grew its holdings in shares of argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company's stock valued at $28,000 after buying an additional 62 shares during the period. J.Safra Asset Management Corp increased its holdings in shares of argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after acquiring an additional 59 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of argenx during the second quarter worth $76,000. Finally, Cromwell Holdings LLC raised its stake in shares of argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after purchasing an additional 66 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of recent research reports. Wolfe Research raised argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price target for the company in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a "buy" rating and issued a $617.00 target price on shares of argenx in a research report on Wednesday, November 20th. Baird R W cut shares of argenx from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 1st. Oppenheimer restated an "outperform" rating and issued a $675.00 price objective (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. Finally, Wells Fargo & Company upped their target price on argenx from $547.00 to $639.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $635.42.

argenx Stock Performance

ARGX traded down $3.01 during trading on Friday, hitting $623.11. The stock had a trading volume of 155,011 shares, compared to its average volume of 308,561. The company has a 50 day moving average price of $574.53 and a 200-day moving average price of $505.00. argenx SE has a one year low of $327.73 and a one year high of $630.00.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the prior year, the company posted ($1.25) earnings per share. Research analysts expect that argenx SE will post 2.2 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.